Almost two years since the start of the pandemic, more drugs to treat COVID patients may be on their way.
of another COVID-19 treatment pill by U.S. pharma companies Ridgeback and Merck. That pill is known in the U.K. as Lagevrio, but it is generally known as molnupiravir.inhibitors, meaning they act to prevent the COVID virus from reproducing in the body. They are both taken orally and are designed to be given to COVID patients.
There is EPIC-SR, which looks at standard-risk patients with a confirmed COVID infection; EPIC-PEP, which looks at healthy adults who live in the same household as someone with COVID; and EPIC-HR, which looks at non-hospitalized high-risk patients with a confirmed COVID infection. The data from the study so far looked at patients 28 days after they were randomized. In the Paxlovid group, in which there were 389 people, three ended up being hospitalized and none of them died.The U.K.'s authorization of molnupiravir followed preliminary analysis of an ongoing Phase 3 clinical trial called MOVe-OUT, in which 800 mg of the drug was given twice daily to non-hospitalized, unvaccinated adult patients with mild-to-moderate COVID-19 infections.
The companies said that through day 29 following randomization, 28 patients were hospitalized or died out of 385 who received molnupiravir, and 53 patients were hospitalized or died out of 377 patients who had received a placebo.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer's COVID-19 pill, Paxlovid, cuts hospitalizations, deaths by 89%'An extraordinary effect': Pfizer says its COVID-19 pill reduced the risk of hospitalization and death by 89% in high-risk patients
Read more »
As China faces its most widespread Covid outbreak since Wuhan, officials double down on zero CovidChina is scrambling to contain its most widespread Covid-19 outbreak since the first wave of infections that began in Wuhan in 2019.
Read more »
Pfizer says its experimental pill reduces risk of hospitalization, death from Covid-19Drugmaker Pfizer said Friday its experimental pill designed to fight coronavirus reduced the risk of hospitalization and death for high-risk patients taking part in a trial of the drug.
Read more »
Pfizer COVID-19 vaccine now available for kids ages 5 to 11: 5 things to knowAn 8-year-old receives his vaccine—and gets a hug from Dr. Bear—at a Washington hospital. What to know as the Pfizer COVID-19 vaccine is now available for kids ages 5 to 11:
Read more »
Factbox: Countries rush to buy Merck experimental COVID-19 pillMerck has signed eight deals to sell more than a total of 2 million courses of its experimental COVID-19 pill molnupiravir to governments around the world as countries scramble to tame the virus.
Read more »